Key facts
- Attovia Therapeutics’s last known valuation is $370.0M (Mar 2025).
- It has raised $255.0M; the latest was Later Stage VC ($90.0M) in Mar 2025.
- Notable investors include Goldman Sachs Asset Management, Cormorant Asset Management, Logos Capital, Frazier Healthcare Partners, Illumina Ventures — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Attovia Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Attovia Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Attovia Therapeutics
Developer of a biotherapeutics pipeline designed for immune-mediated disease and oncology. The company leverages nanobody technology to generate small-format binders with low picomolar affinity, enhanced specificity, accelerated internalization, and rapid tissue penetration, enabling healthcare professionals to treat cancer patients with required therapeutics.
- Sector
- Healthcare
- HQ
- San Carlos, CA, United States
- Founded
- 2023
- Employees
- 50
- Website
- attovia.com/
- Ownership
- Privately Held (backing)
Attovia Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Attovia Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Attovia Therapeutics in its N-PORT filings yet. We sweep new filings monthly.